Discoiding Domain Receptor 1 (DDR1) expression is associated with degree of immune exclusion across epithelial tumors

Discoidin domain receptor 1 (DDR1) is highly expressed in epithelial cancers and has been implicated in tumor growth, invasion, and lack of response to therapy.

DDR1 contributes to immune exclusion by promoting tumor collagen alignment in in vivo models. However, it remains unclear how DDR1 expression affects immune cell infiltration in human tumors.

A first-in-human trial of PRTH-101, a DDR1-targeted therapeutic antibody, is underway.

Establishing a correlation between DDR1 expression and immune infiltration in the tumor microenvironment (TME) will help clarify DDR1’s role in the TME and inform indication and patient selection strategies for DDR1-targeted therapies.